Calcium Channel Blockers

Uses

Dosage & preparation

Risks & contraindications

Comparisons

Evidence quality

Where it comes from

Highlighted claims

• Brain-penetrant CCBs include felodipine, isradipine, nifedipine, and nitrendipine, while non-brain-penetrant CCBs include amlodipine, lacidipine, and levamlodipine. — Lack of association between the brain penetrance of calcium channel blockers and the incidence of neuropsychiatric outcomes: a retrospective, multidatabase cohort study
• The study found no evidence that BP-CCB use was associated with lower or higher risk of any of the four neuropsychiatric outcomes compared with NP-CCB use. — Lack of association between the brain penetrance of calcium channel blockers and the incidence of neuropsychiatric outcomes: a retrospective, multidatabase cohort study
• CCBs in this study were primarily prescribed for hypertension and other cardiovascular conditions, not for neuropsychiatric indications. — Lack of association between the brain penetrance of calcium channel blockers and the incidence of neuropsychiatric outcomes: a retrospective, multidatabase cohort study
• Prior clinical investigations of CCBs for schizophrenia and bipolar disorder produced no consistent or robust benefit and were constrained by small samples, short duration, and cardiovascular dose limits. — Lack of association between the brain penetrance of calcium channel blockers and the incidence of neuropsychiatric outcomes: a retrospective, multidatabase cohort study
• Currently approved CCBs generally cannot be administered at neuropsychiatrically relevant doses because of likely cardiovascular adverse effects. — Lack of association between the brain penetrance of calcium channel blockers and the incidence of neuropsychiatric outcomes: a retrospective, multidatabase cohort study
• The dose of a CCB required to achieve brain exposure sufficient to affect psychiatric outcomes may be higher than doses used in routine cardiovascular care. — Lack of association between the brain penetrance of calcium channel blockers and the incidence of neuropsychiatric outcomes: a retrospective, multidatabase cohort study